CTRI/2010/091/001094CompletedPhase 1
An open-label, randomized, single dose, two period,crossover study to determine the bioavailability ofvalsartan oral solution formulation relative to the valsartan tablet formulation (Diovan®) in healthy adult subjects
ovartis Healthcare Private Limited Andhra Pradesh India0 sites30 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Ba/be
Eligibility Criteria
Inclusion Criteria
- •Healthy males and postmenopausal or surgically sterilized women of 18 to 45 years of age who grant informed consent
Exclusion Criteria
- •Smokers, drug addicts, those having immunodeficiency diseases
Investigators
Similar Trials
Active, not recruiting
Phase 1
Clinical trial in Healthy Volunteers to test Valsartan PharmacokineticsHypertensionEUCTR2016-004323-23-Outside-EU/EEAovartis86
Completed
Not Applicable
Bioavailability study between Pirfenidone ER tablet 1200 mg and PIRFENEX (pirfenidone) 200 mg tablet in healthy human subjectsCTRI/2021/09/036729Cipla Ltd India60
Not yet recruiting
Not Applicable
Bioequialence study of two novel strengths of CoartemCTRI/2011/12/002256ovartis Healthcare Pvt Ltd120
Active, not recruiting
Not Applicable
A research study to find out whether a product to be tested (salmeterol xinafoate HFA pMDI 25 µg per actuation, manufactured by Cipla Ltd, India) is equivalent to the already existing formulation (salmeterol xinafoate HFA pMDI 25 µg per actuation (Serevent Evohaler™), supplied by Allen and Hanburys, UK) when administered by a volumatic spacer device to children with asthmaMedDRA version: 17.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2014-001946-10-BGCipla Ltd.80
Completed
Not Applicable
Randomized, Open Label, Single-Dose, Two Period, Two Treatment, Two Sequence, Cross-over, Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety of Rabeprazole Sodium Delayed-release Capsule 20 mg in Healthy Volunteers.CTRI/2017/07/008985Cadila Healthcare Limited12